The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

Tidepool today announced a new data integration with Abbott for the company's FreeStyle Libre continuous glucose monitors ...

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding ... Continuous ...

Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a ...

Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) ...

Now iLet Users Have a Choice of iCGMs to Customize Their Diabetes ManagementIRVINE, CA / ACCESSWIRE / October 30, 2024 / Beta ...

Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's ...

Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations.

Tidepool collaborates with Abbott for seamless data integration ... to initiate the connection with their patients using FreeStyle Libre 2 and 3 systems in clinic or remotely.

由于第三季度表现强劲，Abbott Laboratories提高了全年利润预期，这主要得益于其医疗设备（包括FreeStyle Libre血糖监测仪）的强劲销售。公司的医疗设备部门报告销售额为47.5亿美元，超过分析师平均预期的46.8亿美元。

A major development towards the goal of patient and provider choice, the cloud-to-cloud integration will provide an automatic stream of data from patients using Abbott’s FreeStyle Libre ...